Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gynecologic 3

Conditions

Sarcoma 523Glioblastoma 179Gliosarcoma 178Osteosarcoma 155Dendritic Cell Sarcoma, Interdigitating 114Brain Neoplasms 113Gastrointestinal Stromal Tumors 108Central Nervous System Neoplasms 102Rhabdomyosarcoma 81Lymphoma 79Glioma 79Burkitt Lymphoma 79Lymphoma, Non-Hodgkin 78Recurrence 76Leiomyosarcoma 75Precursor Cell Lymphoblastic Leukemia-Lymphoma 73Lymphoma, Large B-Cell, Diffuse 70Liposarcoma 69Astrocytoma 68Sarcoma, Ewing 67Lymphoma, Follicular 63Neuroblastoma 60Lymphoma, Mantle-Cell 58Leukemia, Lymphocytic, Chronic, B-Cell 57Lymphoma, B-Cell, Marginal Zone 56Lymphoma, Large-Cell, Immunoblastic 54Hodgkin Disease 54Leukemia, Myeloid, Acute 53Neuroectodermal Tumors, Primitive, Peripheral 52Neoplasm Metastasis 51

Interventions

temsirolimus 1Sorafenib 1Sirolimus 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Recurrent Uterine Sarcoma × Sarcoma × Clear all
NCT00075400 2019-07-24

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

NCT01061606 2016-11-09

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Terminated
8 enrolled 6 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

NCT00238121 2015-11-20

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡